Recently, a pioneering study in a melanoma mouse model showed that BRAF-mutated tumors are resistant to BRAF inhibitors, mainly due to the aberrant activation of cancer-associated fibroblasts (CAFs). The gene discussed is BRAF; the disease is melanoma.